ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody

By The Science Advisory Board staff writers

ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.

Under the agreement, ImmunoPrecise will use Zymeworks' Azymetric and Efect platforms to further develop multiple COVID-19 monospecific antibody candidates by transforming them into bispecific and multispecific antibodies, the companies said.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking